


Urinary catheter T-Control

The problem of catheterization



Urine retention
Incontinence

- Prostate hypertrophy
- Surgical interventions
- Recovery period
- Multiple sclerosis
- Spinal cord injury
- Age related incontinence
- Other illness

192 million units forecasted for 2019


Quality of life
psychological, social, physical
Bladder reflex
chronic incontinence

Frequent Emergency visits
blockage, leakage, pain

Catheter related infections in Europe:


>14.000 death/year
1.8 bn eur direct cost

Almost 100 % chance after 4 weeks



21.1% of the world's population by 2050 (>65 years) → Proliferation of illnesses

The first and only catheter with three additional functions vs current gold standard



Competitive differentiation - advantages

- PATIENT**
 - Quality of life improvement, independence, flexibility and easier acceptance of the basic disease
 - Avoidance of psychological/physical/social problems caused by sedentary and introverted lifestyle
 - Lower risk of infection and blockage (less emergency visit, shorter hospital stay, lower death rate)
 - Avoidance of bladder reflex loss (incontinence problems after catheter removal)
 - Easy-to-handle, safe and scientifically proven catheter
- HCP**
 - Easier adherence to protocols (safety) and possibility of inserting the catheter in sterile form by one person only (instead of two)
 - Decreased risk of accidental contamination of the hospital staff or urine sample
 - Decreased stress, workload and material used
 - Significant overall cost reduction related to catheters

2017: Winner of EIT Health Headstart competition (50k EUR)
2018: Cimiti Accelerator Program
2018: SME Instrument Phase I. (50k EUR)



Timeline

2014-2017	2018				2019				2020				2021				
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	
IP & prototypes																	
		Final product manufacturing															
			Registration														
				Clinical trial													
					Commercialization												
						Introduction											
									Uptake								

- Patented in USA & EU
- Clean room
- Economy of scale
- Cost minimization
- Wide Bibliographic data available
- Based on non-inferiority vs UCs and accessories
- Europe, USA & Canada

Funds to be raised: 1,4m EUR
Exit opportunity: 2020
3 year ROI > 5x

Founders:



Szilvia Endrényi
Economist
Co-founder & CEO
szilvia@rethinkmedical.es



Manuel Luque
Nurse
Co-founder & CTO
mluque@rethinkmedical.es